| 1. |
- Rossi, A., et al.
(författare)
-
A blast from the infant Universe : The very high-z GRB210905A
- 2022
-
Ingår i: Astronomy and Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 665
-
Tidskriftsartikel (refereegranskat)abstract
- We present a detailed follow-up of the very energetic GRB 210905A at a high redshift of z = 6.312 and its luminous X-ray and optical afterglow. Following the detection by Swift and Konus-Wind, we obtained a photometric and spectroscopic follow-up in the optical and near-infrared (NIR), covering both the prompt and afterglow emission from a few minutes up to 20 Ms after burst. With an isotropic gamma-ray energy release of Eiso = 1.27−0.19+0.20 × 1054 erg, GRB 210905A lies in the top ∼7% of gamma-ray bursts (GRBs) in the Konus-Wind catalogue in terms of energy released. Its afterglow is among the most luminous ever observed, and, in particular, it is one of the most luminous in the optical at t ≳ 0.5 d in the rest frame. The afterglow starts with a shallow evolution that can be explained by energy injection, and it is followed by a steeper decay, while the spectral energy distribution is in agreement with slow cooling in a constant-density environment within the standard fireball theory. A jet break at ∼46.2 ± 16.3 d (6.3 ± 2.2 d rest-frame) has been observed in the X-ray light curve; however, it is hidden in the H band due to a constant contribution from the host galaxy and potentially from a foreground intervening galaxy. In particular, the host galaxy is only the fourth GRB host at z > 6 known to date. By assuming a number density n = 1 cm−3 and an efficiency η = 0.2, we derived a half-opening angle of 8.4 ° ±1.0°, which is the highest ever measured for a z ≳ 6 burst, but within the range covered by closer events. The resulting collimation-corrected gamma-ray energy release of ≃1 × 1052 erg is also among the highest ever measured. The moderately large half-opening angle argues against recent claims of an inverse dependence of the half-opening angle on the redshift. The total jet energy is likely too large to be sustained by a standard magnetar, and it suggests that the central engine of this burst was a newly formed black hole. Despite the outstanding energetics and luminosity of both GRB 210905A and its afterglow, we demonstrate that they are consistent within 2σ with those of less distant bursts, indicating that the powering mechanisms and progenitors do not evolve significantly with redshift.
|
|
| 2. |
- Saccardi, R, et al.
(författare)
-
Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
- 2023
-
Ingår i: Bone marrow transplantation. - : Springer Science and Business Media LLC. - 1476-5365 .- 0268-3369. ; 58:6, s. 659-666
-
Tidskriftsartikel (refereegranskat)abstract
- From 2016 EBMT and JACIE developed an international risk-adapted benchmarking program of haematopoietic stem cell transplant (HSCT) outcome to provide individual EBMT Centers with a means of quality-assuring the HSCT process and meeting FACT-JACIE accreditation requirements relating to 1-year survival outcomes. Informed by previous experience from Europe, North America and Australasia, the Clinical Outcomes Group (COG) established criteria for patient and Center selection, and a set of key clinical variables within a dedicated statistical model adapted to the capabilities of the EBMT Registry. The first phase of the project was launched in 2019 to test the acceptability of the benchmarking model through assessment of Centers’ performance for 1-year data completeness and survival outcomes of autologous and allogeneic HSCT covering 2013–2016. A second phase was delivered in July 2021 covering 2015–2019 and including survival outcomes. Reports of individual Center performance were shared directly with local principal investigators and their responses were assimilated. The experience thus far has supported the feasibility, acceptability and reliability of the system as well as identifying its limitations. We provide a summary of experience and learning so far in this ‘work in progress’, as well as highlighting future challenges of delivering a modern, robust, data-complete, risk-adapted benchmarking program across new EBMT Registry systems.
|
|
| 3. |
- Greco, R, et al.
(författare)
-
Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations
- 2021
-
Ingår i: Bone marrow transplantation. - : Springer Science and Business Media LLC. - 1476-5365 .- 0268-3369. ; 56:7, s. 1493-1508
-
Tidskriftsartikel (refereegranskat)abstract
- Coronavirus disease-19 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), represents one of the biggest challenges of 21st century, threatening public health around the globe. Increasing age and presence of co-morbidities are reported risk factors for severe disease and mortality, along with autoimmune diseases (ADs) and immunosuppressive treatments such as haematopoietic stem cell transplantation (HSCT), which are also associated with adverse outcomes. We review the impact of the pandemic on specific groups of patients with neurological, rheumatological, and gastroenterological indications, along with the challenges delivering HSCT in adult and pediatric populations. Moving forward, we developed consensus-based guidelines and recommendations for best practice and quality of patient care in order to support clinicians, scientists, and their multidisciplinary teams, as well as patients and their carers. These guidelines aim to support national and international organizations related to autoimmune diseases and local clinical teams delivering HSCT. Areas of unmet need and future research questions are also highlighted. The waves of the COVID-19 pandemic are predicted to be followed by an “endemic” phase and therefore an ongoing risk within a “new normality”. These recommendations reflect currently available evidence, coupled with expert opinion, and will be revised according to necessary modifications in practice.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Snowden, JA, et al.
(författare)
-
Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
- 2020
-
Ingår i: Bone marrow transplantation. - : Springer Science and Business Media LLC. - 1476-5365 .- 0268-3369. ; 55:4, s. 681-694
-
Tidskriftsartikel (refereegranskat)abstract
- In many healthcare settings, benchmarking for complex procedures has become a mandatory requirement by competent authorities, regulators, payers and patients to assure clinical performance, cost-effectiveness and safe care of patients. In several countries inside and outside Europe, benchmarking systems have been established for haematopoietic stem cell transplantation (HSCT), but access is not universal. As benchmarking is now integrated into the FACT-JACIE standards, the EBMT and JACIE established a Clinical Outcomes Group (COG) to develop and introduce a universal system accessible across EBMT members. Established systems from seven European countries (United Kingdom, Italy, Belgium, France, Germany, Spain, Switzerland), USA and Australia were appraised, revealing similarities in process, but wide variations in selection criteria and statistical methods. In tandem, the COG developed the first phase of a bespoke risk-adapted international benchmarking model for one-year survival following allogeneic and autologous HSCT based on current capabilities within the EBMT registry core dataset. Data completeness, which has a critical impact on validity of centre comparisons, is also assessed. Ongoing development will include further scientific validation of the model, incorporation of further variables (when appropriate) alongside implementation of systems for clinically meaningful interpretation and governance aiming to maximise acceptance to centres, clinicians, payers and patients across EBMT.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
